CORRESP Filing
InMed Pharmaceuticals Inc.
Date: March 26, 2026 · CIK: 0001728328 · Accession: 0001213900-26-034689
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294503
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Registration Statement on Form S-3 Filed March 20, 2026 File No.: 333-294503
Re: InMed Pharmaceuticals Inc.
Dear Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, InMed Pharmaceuticals Inc. hereby respectfully requests that the effectiveness of the above-referenced Registration Statement on Form S-3 (File No.: 333-294503) be accelerated to occur at 5:00 p.m., New York City time, on March 30, 2026 or as soon thereafter as practicable.
It would be appreciated if you would inform Scott Saks at Norton Rose Fulbright US LLP at +1-212-318-3151 once the above referenced Registration Statement is declared effective.
Very truly yours,
InMed Pharmaceuticals Inc.
Show Raw Text
CORRESP 1 filename1.htm March 26, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: InMed Pharmaceuticals Inc. Registration Statement on Form S-3 Filed March 20, 2026 File No.: 333-294503 Dear Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, InMed Pharmaceuticals Inc. hereby respectfully requests that the effectiveness of the above-referenced Registration Statement on Form S-3 (File No.: 333-294503) be accelerated to occur at 5:00 p.m., New York City time, on March 30, 2026 or as soon thereafter as practicable. It would be appreciated if you would inform Scott Saks at Norton Rose Fulbright US LLP at +1-212-318-3151 once the above referenced Registration Statement is declared effective. Very truly yours, InMed Pharmaceuticals Inc. By: /s/ Netta Jagpal Name: Netta Jagpal Title: Chief Financial Officer cc: Scott Saks (Norton Rose Fulbright US LLP)